News
Silence Therapeutics is snatching back two siRNA drug | Silence Therapeutics is snatching back two siRNA drug targets developed through a $20 million collaboration with Mallinckrodt Pharmaceuticals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback